Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2637

1.
2.

Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.

Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS.

J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):522-6.

PMID:
12679704
3.

Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy.

Palepu A, Tyndall MW, Li K, Yip B, O'Shaughnessy MV, Schechter MT, Montaner JS, Hogg RS.

J Urban Health. 2003 Dec;80(4):667-75.

5.

Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.

Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, Hogg RS, Montaner JS.

Drug Alcohol Depend. 2006 Sep 15;84(2):188-94. Epub 2006 Mar 20.

PMID:
16542797
6.

Outpatient pharmacy care and HIV viral load response among patients on HAART.

Castillo E, Palepu A, Beardsell A, Akagi L, Yip B, Montaner JS, Hogg RS.

AIDS Care. 2004 May;16(4):446-57.

PMID:
15203413
7.

Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort.

Kuyper LM, Wood E, Montaner JS, Yip B, O'connell JM, Hogg RS.

J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1470-6.

PMID:
15602125
8.
9.

Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.

Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, Clotet B.

Arch Intern Med. 2000 Apr 24;160(8):1123-32.

PMID:
10789605
10.

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.

PMID:
17438315
11.
12.

Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.

Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B; MANIF 2000 Study Group.

Antivir Ther. 2005;10(1):53-61.

PMID:
15751763
14.

Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme.

O'Connell JM, Braitstein P, Hogg RS, Yip B, Craib KJ, O'Shaughnessy MV, Montaner JS, Burdge DR.

Antivir Ther. 2003 Dec;8(6):569-76.

PMID:
14760890
15.

[Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment].

Pavie J, Porcher R, Fournier S, André F, Tournoux C, Palmer P, Rabian C, Jean-Michel M.

Presse Med. 2005 Jun 4;34(10 Suppl):1S8-13. French.

PMID:
16025661
16.

Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.

Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, Montaner JS.

AIDS. 2008 Nov 12;22(17):2371-80. doi: 10.1097/QAD.0b013e328315cdd3.

PMID:
18981777
17.
18.
19.

Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.

Lima VD, Gill VS, Yip B, Hogg RS, Montaner JS, Harrigan PR.

J Infect Dis. 2008 Jul 1;198(1):51-8. doi: 10.1086/588675.

20.

Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting.

Nolan S, Milloy MJ, Zhang R, Kerr T, Hogg RS, Montaner JS, Wood E.

AIDS Care. 2011 Aug;23(8):980-7. doi: 10.1080/09540121.2010.543882.

PMID:
21480010
Items per page

Supplemental Content

Write to the Help Desk